PCOS Research & Resources
Peer-reviewed clinical evidence, patient education guides, and curated resources on PCOS, insulin resistance, and GLP-1 treatment — organized for patients, not just physicians.
Medical Disclaimer: The research summaries on this page are provided for educational purposes only. They do not constitute medical advice. GLP-1 medications are prescribed off-label for PCOS by licensed physicians based on individual patient evaluation. Always consult a qualified healthcare provider before starting any treatment.
Clinical Research on GLP-1 & PCOS
The following summaries are based on published, peer-reviewed research. Citations are provided for verification. Individual results vary.
GLP-1 Receptor Agonists in Women with PCOS: A Systematic Review and Meta-Analysis
De Hollanda A, et al.
GLP-1 RAs significantly reduced BMI, waist circumference, and total testosterone in women with PCOS. Menstrual cycle regularity improved in a significant proportion of treated patients.
Liraglutide in Polycystic Ovary Syndrome: Menstrual Regularity, Ovarian Volume, and Androgen Levels
Monney M, et al.
Liraglutide treatment resulted in improved menstrual bleeding regularity, decreased ovarian volume, and reduced free testosterone levels in women with PCOS.
GLP-1 Receptor Agonists and Ovulatory Function in PCOS: Mechanisms and Clinical Outcomes
Hoteit R, et al.
GLP-1 RAs may reduce serum androgen levels, enhance ovulatory function, and support menstrual cycle normalization through improvements in insulin sensitivity.
Semaglutide vs. Metformin in PCOS: Comparative Metabolic and Hormonal Outcomes
Xiao Y, et al.
Semaglutide demonstrated superior weight loss outcomes compared to metformin and showed greater reductions in testosterone and improvements in insulin resistance markers.
Tirzepatide in Women with PCOS and Obesity: Hormonal and Metabolic Effects
Cena H, et al.
Tirzepatide's dual GLP-1/GIP mechanism showed enhanced insulin sensitization and greater reductions in androgen levels compared to GLP-1 monotherapy in women with PCOS.
Insulin Resistance as the Central Pathophysiological Mechanism of PCOS
Diamanti-Kandarakis E, Dunaif A.
Landmark review establishing insulin resistance as the central driver of PCOS pathophysiology, with hyperinsulinemia stimulating ovarian androgen production. Foundational to current treatment approaches.
Written for Patients, Not Physicians
Plain-language guides on PCOS, treatment options, and what to expect — reviewed for clinical accuracy.
Understanding Your PCOS Diagnosis
What the Rotterdam criteria mean, which lab tests to ask for, and how to interpret your results.
Why Standard Diets Fail for PCOS
The metabolic reasons why calorie restriction alone rarely works — and what actually does.
PCOS & Fertility: What GLP-1 Can and Can't Do
Honest guidance on ovulatory function, fertility, and what to discuss with your physician.
Exercise, Diet & GLP-1: What to Combine
Evidence-based lifestyle guidance for women on GLP-1 therapy for PCOS.
Semaglutide vs. Tirzepatide for PCOS
Head-to-head comparison of GLP-1 and GLP-1/GIP dual agonist options for PCOS.
PCOS Treatment Safety Guide
Side effects, contraindications, and safety monitoring for GLP-1 therapy in PCOS.
Deep Dives on PCOS & GLP-1
GLP-1 Medications & Menstrual Regularity
Clinical evidence on menstrual cycle restoration with semaglutide and tirzepatide.
PCOS & Insulin Resistance: The Connection
Why up to 80% of PCOS cases are rooted in insulin resistance — and what that means for treatment.
Food Noise, Cravings & PCOS
How insulin resistance amplifies hunger signals — and how GLP-1 medications quiet them.
PCOS in Perimenopause & Menopause
How PCOS symptoms evolve with age and what changes in treatment approach.
Semaglutide for PCOS: What the Research Shows
A review of peer-reviewed studies on semaglutide outcomes in women with PCOS.